Prescription Costs Surpassing Mortgages: The Failure of Valuation Mathematics

Paying more for prescription drugs than a monthly mortgage is no longer an anomaly but a symptom of a systemic market failure. This crisis stems directly from allowing the entities developing the drugs to unilaterally dictate the correlation between a drug's value and its price.

The Monopoly on Value Definition

The pricing mechanism within the pharmaceutical industry prioritizes corporate profit targets over consumer purchasing power. This structure creates an artificial price bubble in the market while threatening accessibility.

■Drug prices have escalated to compete directly with essential living costs like housing loans.

■The lack of independent auditing in valuation processes disrupts market equilibrium.

■Affordability is being crushed under monopolistic corporate decisions.

Sustainability and Cost Control

From an economic sustainability perspective, this pricing model threatens to bankrupt healthcare insurance systems in the medium term. Market dynamics cannot return to normal amidst these artificial barriers created by the supply side.

Similar to the pricing powers seen in Mega-Cap technology companies, the valuation models determined solely by pharma giants may promise high returns to investors in the short term, but they harbor a serious systemic risk for macroeconomic stability. Such intense concentration of capital renders market pricing mechanisms dysfunctional.